Managing myelodysplastic syndromes (MDS) – from diagnosis to treatment 

Myelodysplastic syndrome (MDS), or myelodysplasia, is a blood disorder that causes a drop in your number of healthy blood cells. MDS covers a spectrum of disorders from indolent (slow developing) to aggressive (that rapidly develop or change into leukaemia).

MDS can affect people of any age, but is most common in people over the age of 65. Only one in five people with MDS are younger than 50. For most people, symptoms are mild at first and slowly get worse. Sometimes you may even have no symptoms at all, but have had a blood test that shows there is a problem. The treatment of MDS is constantly evolving and new drugs are being tested all the time.

Our expert is consultant haematologist Dr Beth Payne who specialises in treating patients with myelodysplastic syndromes and bone marrow failure. She is also a Senior Clinical Researcher funded by the Wellcome Trust and The Leuka John Goldman Fellowship for future Science and runs a research laboratory studying the mechanisms of disease in bone marrow failure and myelodysplastic syndromes and is also working to develop novel therapeutics.

Live Blog Managing myelodysplastic syndromes (MDS) – from diagnosis to treatment

 Useful links